Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil

被引:0
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Montoro, Juan [3 ]
Pinana, Jose Luis [4 ]
Ferra, Christelle [5 ]
Herruzo, Beatriz [2 ]
Garcia-Cadenas, Irene [1 ]
Balaguer, Aitana [3 ]
Perez, Ariadna [4 ]
Huguet, Maria [5 ]
Redondo, Sara [1 ]
Villalba, Marta [3 ]
Hernandez-Boluda, Juan Carlos [4 ]
Chorao, Pedro [3 ]
Hernani, Rafael [4 ]
Sanz, Jaime [3 ]
Solano, Carlos [4 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Universitari & Politecn La Fe, Dept Hematol, Valencia, Spain
[4] Hosp Clin Univ, Hematol Dept, Valencia, Spain
[5] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2024年 / 30卷 / 10期
关键词
Haploidentical stem cell; transplantation; TBF conditioning; Haploidentical GVHD; prophylaxis; Tacrolimus versus sirolimus; BONE-MARROW-TRANSPLANTATION; STANDARD-OF-CARE; BLOOD STEM-CELLS; POSTTRANSPLANT CYCLOPHOSPHAMIDE; GVHD PROPHYLAXIS; HEMATOLOGIC MALIGNANCIES; PHASE-II; DONOR; METHOTREXATE; CYCLOSPORINE;
D O I
10.1016/j.jtct.2024.07.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the introduction of post-transplantation cyclophosphamide (PTCy), haploidentical hematopoietic stem cell transplantation (haploSCT) has become a real alternative for patients who lack other eligible donors. The standard graft-versus-host disease (GVHD) prophylaxis after PTCy has been a calcineurin inhibitor (CNI) plus mycophenolate mofetil (MMF) (up to day +35), but promising results with sirolimus (with or without MMF) and single-agent tacrolimus have been published recently. This multicenter retrospective study compared the outcomes of 372 adult haploSCT recipients who received conditioning with thiotepa, busulfan, and fludarabine (TBF), PTCy, and additional GVHD prophylaxis with 1 of 3 strategies: cohort A, single-agent tacrolimus (n = 222); cohort B, CNI + MMF (n = 49); or cohort C, sirolimus + MMF (n = 101). No differences among the 3 cohorts were found in terms of grade II-IV acute GVHD (20% in cohort A, 25% in cohort B, and 30% in cohort C) or grade III-IV acute GVHD (9%, 6%, and 15%, respectively) at 100 days; however, cohort A had the lowest incidence of overall chronic GVHD (24%, 47%, and 52%, respectively; P = .001) and moderatesevere chronic GVHD (13%, 35%, and 33%, respectively; P = .001). There were no differences in 3-year overall survival, progression-free survival, nonrelapse mortality, or relapse among the 3 cohorts. Overall, our study suggests that single-agent tacrolimus, CNI + MMF, and sirolimus + MMF GVHD prophylaxis lead to similar outcomes following haploSCT with TBF and PTCy, with a low incidence of grade III-IV acute GVHD, although possible differences in chronic GVHD require further investigation. (c) 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1025e1 / 1025e14
页数:14
相关论文
共 42 条
[11]   Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial [J].
Broers, Annoek E. C. ;
de Jong, Cornelis N. ;
Bakunina, Katerina ;
Hazenberg, Mette D. ;
Kooy, Marinus van Marwijk ;
de Groot, Marco R. ;
van Gelder, Michel ;
Kuball, Jurgen ;
van der Holt, Bronno ;
Meijer, Ellen ;
Cornelissen, Jan J. .
BLOOD ADVANCES, 2022, 6 (11) :3378-3385
[12]   Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells [J].
Cieri, Nicoletta ;
Greco, Raffaella ;
Crucitti, Lara ;
Morelli, Mara ;
Giglio, Fabio ;
Levati, Giorgia ;
Assanelli, Andrea ;
Carrabba, Matteo G. ;
Bellio, Laura ;
Milani, Raffaella ;
Lorentino, Francesca ;
Stanghellini, Maria Teresa Lupo ;
De Freitas, Tiago ;
Marktel, Sarah ;
Bernardi, Massimo ;
Corti, Consuelo ;
Vago, Luca ;
Bonini, Chiara ;
Ciceri, Fabio ;
Peccatori, Jacopo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (08) :1506-1514
[13]   Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia [J].
Ciurea, Stefan O. ;
Zhang, Mei-Jie ;
Bacigalupo, Andrea A. ;
Bashey, Asad ;
Appelbaum, Frederick R. ;
Aljitawi, Omar S. ;
Armand, Philippe ;
Antin, Joseph H. ;
Chen, Junfang ;
Devine, Steven M. ;
Fowler, Daniel H. ;
Luznik, Leo ;
Nakamura, Ryotaro ;
O'Donnell, Paul V. ;
Perales, Miguel-Angel ;
Pingali, Sai Ravi ;
Porter, David L. ;
Riches, Marcie R. ;
Ringden, Olle T. H. ;
Rocha, Vanderson ;
Vij, Ravi ;
Weisdorf, Daniel J. ;
Champlin, Richard E. ;
Horowitz, Mary M. ;
Fuchs, Ephraim J. ;
Eapen, Mary .
BLOOD, 2015, 126 (08) :1033-1040
[14]   Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation [J].
Cutler, Corey ;
Li, Shuli ;
Ho, Vincent T. ;
Koreth, John ;
Alyea, Edwin ;
Soiffer, Robert J. ;
Antin, Joseph H. .
BLOOD, 2007, 109 (07) :3108-3114
[15]   Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT [J].
Cutler, Corey ;
Logan, Brent ;
Nakamura, Ryotaro ;
Johnston, Laura ;
Choi, Sung ;
Porter, David ;
Hogan, William J. ;
Pasquini, Marcelo ;
MacMillan, Margaret L. ;
Hsu, Jack W. ;
Waller, Edmund K. ;
Grupp, Stephan ;
McCarthy, Philip ;
Wu, Juan ;
Hu, Zhen-Huan ;
Carter, Shelly L. ;
Horowitz, Mary M. ;
Antin, Joseph H. .
BLOOD, 2014, 124 (08) :1372-1377
[16]   Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen Matched Unrelated and Related Donors [J].
Di Stasi, Antonio ;
Milton, Dendi R. ;
Poon, L. M. ;
Hamdi, Amir ;
Rondon, Gabriela ;
Chen, Julianne ;
Pingali, Sai R. ;
Konopleva, Marina ;
Kongtim, Piyanuch ;
Alousi, Amin ;
Qazilbash, Muzaffar H. ;
Ahmed, Sairah ;
Bashir, Qaiser ;
Al-atrash, Gheath ;
Oran, Betul ;
Hosing, Chitra M. ;
Kebriaei, Partow ;
Popat, Uday ;
Shpall, Elizabeth J. ;
Lee, Dean A. ;
de Lima, Marcos ;
Rezvani, Katayoun ;
Khouri, Issa F. ;
Champlin, Richard E. ;
Ciurea, Stefan O. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) :1975-1981
[17]   Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation [J].
Dulery, Remy ;
Bastos, Juliana ;
Paviglianiti, Annalisa ;
Malard, Florent ;
Brissot, Eolia ;
Battipaglia, Giorgia ;
Mediavilla, Clemence ;
Giannotti, Federica ;
Banet, Anne ;
Van de Wyngaert, Zoe ;
Ledraa, Tounes ;
Belhocine, Ramdane ;
Sestili, Simona ;
Adaeva, Rosa ;
Lapusan, Simona ;
Isnard, Francoise ;
Legrand, Ollivier ;
Vekhoff, Anne ;
Rubio, Marie-Therese ;
Ruggeri, Annalisa ;
Mohty, Mohamad .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (07) :1407-1415
[18]   Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide [J].
Elmariah, Hany ;
Otoukesh, Salman ;
Kumar, Ambuj ;
Ali, Haris ;
Arslan, Shukaib ;
Shouse, Geoffrey ;
Pourhassan, Hoda ;
Nishihori, Taiga ;
Faramand, Rawan ;
Mishra, Asmita ;
Khimani, Farhad ;
Fernandez, Hugo ;
Lazaryan, Aleksandr ;
Nieder, Michael ;
Perez, Lia ;
Liu, Hien ;
Nakamura, Ryotaro ;
Pidala, Joseph ;
Marcucci, Guido ;
Forman, Stephen J. ;
Anasetti, Claudio ;
Locke, Frederick ;
Bejanyan, Nelli ;
Malki, Monzr M. Al .
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (02) :e1-e11
[19]   Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies [J].
Esquirol, A. ;
Pascual, M. J. ;
Ortiz, M. ;
Pinana, J. L. ;
Ferra, C. ;
Garcia Cadenas, I. ;
Vilades, I. ;
Brunet, S. ;
Martino, R. ;
Sierra, J. .
BONE MARROW TRANSPLANTATION, 2017, 52 (09) :1273-1279
[20]   Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide [J].
Esquirol, Albert ;
Jesus Pascual, Maria ;
Garcia-Cadenas, Irene ;
Herruzo, Beatriz ;
Ferra, Christelle ;
Perez, Ariadna ;
Torio, Alberto ;
Torrent, Anna ;
Cuesta, Marian ;
Martino, Rodrigo ;
Sierra, Jorge .
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (07) :614.e1-614.e8